NCT03676959View on ClinicalTrials.gov

A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

May 15, 2022

Study Completion Date

October 15, 2022

Conditions
Cervical Cancer
Interventions
DRUG

ZKAB001 5mg/kg

5mg/kg/times bi-week IV administration of ZKAB001

DRUG

ZKAB001 10mg/kg

10mg/kg/times bi-week IV administration of ZKAB001

DRUG

ZKAB001 15mg/kg

15mg/kg/times bi-week IV administration of ZKAB001

Trial Locations (1)

100000

RECRUITING

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY